Compounds > 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid
Page last updated: 2024-09-03

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Response Evaluation Criteria in Solid Tumors

1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid has been researched along with Response Evaluation Criteria in Solid Tumors in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Berntzen, DT; Løitegård, T; Thiis-Evensen, E1

Other Studies

1 other study(ies) available for 1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid and Response Evaluation Criteria in Solid Tumors

ArticleYear
The RECIST criteria compared to conventional response evaluation after peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms.
    Annals of nuclear medicine, 2019, Volume: 33, Issue:3

    Topics: Adult; Aged; Disease Progression; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Progression-Free Survival; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Tomography, X-Ray Computed; Tumor Burden

2019